EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1)
详细信息 查看全文
- 作者：Tzyh-Chyuan Hour ; Shiu-Dong Chung ; Wang-Yi Kang ; Ying-Chu Lin…
- 关键词：Castration ; resistant prostate cancer ; Epidermal growth factor receptor ; Docetaxel ; Gefitninb ; Chemoresistance
- 刊名：Archives of Toxicology
- 出版年：2015
- 出版时间：April 2015
- 年：2015
- 卷：89
- 期：4
- 页码：591-605
- 全文大小：2,166 KB
- 参考文献：1. Altavilla, A, Iacovelli, R, Procopio, G, Alesini, D, Risi, E, Campenni, GM, Palazzo, A, Cortesi, E (2012) Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant. Cancer Biol Ther 13: pp. 1001-1008 CrossRef
2. Attar, RM, Takimoto, CH, Gottardis, MM (2009) Castration-resistant prostate cancer: locking up the molecular escape routes. Clin Cancer Res 15: pp. 3251-3255 CrossRef
3. Bakin, RE, Gioeli, D, Sikes, RA, Bissonette, EA, Weber, MJ (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63: pp. 1981-1989
4. Barton, S, Starling, N, Swanton, C (2010) Predictive molecular markers of response to epidermal growth factor receptor(EGFR) family-targeted therapies. Curr Cancer Drug Targets 10: pp. 799-812 CrossRef
5. Beer, TM, El-Geneidi, M, Eilers, KM (2003) Docetaxel (taxotere) in the treatment of prostate cancer. Expert Rev Anticancer Ther 3: pp. 261-268 CrossRef
6. Best, CJ, Gillespie, JW, Yi, Y, Chandramouli, GV, Perlmutter, MA, Gathright, Y, Erickson, HS, Georgevich, L, Tangrea, MA, Duray, PH, Gonzalez, S, Velasco, A, Linehan, WM, Matusik, RJ, Price, DK, Figg, WD, Emmert-Buck, MR, Chuaqui, RF (2005) Molecular alterations in primary prostate cancer after androgen ablation therapy. Clin Cancer Res 11: pp. 6823-6834 CrossRef
7. Blagosklonny, MV, Schulte, T, Nguyen, P, Trepel, J, Neckers, LM (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56: pp. 1851-1854
8. Brawer, MK, Crawford, ED, Labrie, F, Mendoza-Valdes, A, Miller, PD, Petrylak, DP (2001) Androgen deprivation and other treatments for advanced prostate cancer. Rev Urol 3: pp. S59-S68
9. Chang, JC, Wooten, EC, Tsimelzon, A, Hilsenbeck, SG, Gutierrez, MC, Elledge, R, Mohsin, S, Osborne, CK, Chamness, GC, Allred, DC, O’Connell, P (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 362: pp. 362-369 CrossRef
10. Choudhury, AD, Eeles, R, Freedland, SJ, Isaacs, WB, Pomerantz, MM, Schalken, JA, Tammela, TL, Visakorpi, T (2012) The role of genetic markers in the management of prostate cancer. Eur Urol 62: pp. 577-587 CrossRef
11. Davis, JM, Navolanic, PM, Weinstein-Oppenheimer, CR, Steelman, LS, Hu, W, Konopleva, M, Blagosklonny, MV, McCubrey, JA (2003) Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 9: pp. 1161-1170
12. Dhomen, NS, Mariadason, J, Tebbutt, N, Scott, AM (2012) Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 17: pp. 31-50 CrossRef
13. Di, LG, Tortora, G, D’Armiento, FP, De, RG, Staibano, S, Autorino, R, D’Armiento, M, De, LM, De, PS, Catalano, G, Bianco, AR, Ciardiello, F (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: pp. 3438-3444
14. Domingo-Domenech, J, Oliva, C, Rovira, A, Codony-Servat, J, Bosch, M, Filella, X, Montagut, C, Tapia, M, Campas, C, Dang, L, Rolfe, M, Ross, JS, Gascon, P, Albanell, J, Mellado, B (2006) Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 12: pp. 5578-5586 CrossRef
15. Fry, MJ (2001) Phosphoinositide 3-kinase signalling in breast cancer: how big a role might it play?. Breast Cancer Res 3: pp. 304-312 CrossRef< - 刊物主题：Pharmacology/Toxicology; Occupational Medicine/Industrial Medicine; Environmental Health; Biomedicine general;
- 出版者：Springer Berlin Heidelberg
- ISSN：1432-0738
文摘
Recent studies have shown that docetaxel-based chemotherapy confers a survival benefit in patients with castration-resistant prostate cancer (PC). Also epidermal growth factor receptor (EGFR) was found to have multiple roles in prostatic tumorigenesis. However, the EGFR-mediated chemoresistance mechanism in human PC was not well delineated. In this study, we explored the mechanism of EGFR-mediated docetaxel resistance in PC. A series of stable docetaxel-resistant PC/DX sublines were established at our laboratory. The docetaxel IC50s of PC3 and PC/DX25 cells were 0.01 and 1.33?μM, respectively. Cellular resistance to docetaxel was significantly associated with increased EGFR and EGFR activation in PC/DX25. There was a dose-dependent increase in EGFR expression associated with the magnitude of docetaxel resistance. Expression of EGFR in PC/DX25 was higher than that in PC3, RWPE-1 and LNCaP cells. Similar results were also found in human PC tissues by immunohistochemical staining. We showed that docetaxel sensitivity can be stored in PC/DX25 cells by knockdown and inactivation of EGFR expression through EGFR siRNA and specific inhibitors, respectively. Contrarily, overexpression of EGFR or recombinant EGF protein treatment could rescue PC3 cells from docetaxel-mediated cytotoxicity. Gefitninb (ZD1839) significantly inhibited the growth of PC/DX25 cells by MTT in vitro and on xenografted nude mice in vivo. Moreover, EGFR-mediated docetaxel resistance occurred through the Akt-dependent ABCB1 expression in PC cells. These findings demonstrated EGFR played an important role in docetaxel-resistant PC and EGFR inhibition may enhance the therapeutic efficacy of docetaxel-based treatment.